OverviewSuggest Edit

Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability. Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO®) and the second (DUKORAL®) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant). Valneva is incorporated in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Scotland and Sweden with approximately 400 employees.
TypePublic
HQLyon, FR
Websitevalneva.com

Latest Updates

Employees (est.) (Oct 2016)17,686
Share Price (Oct 2017)€4.6 (+2%)

Key People/Management at Valneva

Thomas Lingelbach

Thomas Lingelbach

President & Chief Executive Officer

Valneva Office Locations

Valneva has offices in Lyon, Saint-Herblain, Gaithersburg, Wien and in 4 other locations
Lyon, FR (HQ)
70, rue Saint Jean de Dieu
Saint-Herblain, FR
6 Rue Alain Bombard
Wien, AT
Campus-Vienna-Biocenter 1
Kirkland, CA
3535 Boulevard Saint-Charles #600
Solna, SE
Gunnar Asplunds allé 16
Fleet, GB
Centaur House, Ancells Business Park
Show all (8)

Valneva Financials and Metrics

Valneva Revenue

Market capitalization (31-Oct-2017)

2.1b

Closing stock price (31-Oct-2017)

4.6
Valneva's current market capitalization is €2.1 b.
Show all financial metrics

Valneva Online and Social Media Presence

Embed Graph

Valneva News and Updates

Focus on Traveler's Diarrhea Therapeutics Market Changing the Way of Business in Upcoming Year with Profiling Key P&G, Valneva, PaxVax, Livzon

The Traveler's Diarrhea Therapeutics market was valued at xx Million US$ in 2020 and is projected to reach xx Million US$ by 2026, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size…

Valneva Expands its Commercial Operations with the Opening of its French Commercial Office

Saint-Herblain (France), January 9, 2020 – Valneva SE (“Valneva” or “the Company”) today announced a further expansion of its global commercial infrastructure with the opening of a French commercial office in Lyon. The fully owned commercial subsidiary, Valneva France SAS, will take direct control o…

Valneva Announces EMA Approval of IXIARO® Shelf Life Extension to 36 Months

Saint Herblain (France), November 28, 2019 – Valneva SE (“Valneva” or “the Company”), today announced that the European Medicines Agency (EMA) has approved the extension of the shelf life of its Japanese encephalitis vaccine IXIARO® from 24 months to 36 months.

Valneva Raises Product Sales Guidance Following Strong Nine-Month Results and R&D Execution

Company product sales guidance raised for FY 2019, EBITDA confirmed

Lyme Disease H2 2019 Pipeline Review, with Focus on Key Players such as Inovio Pharmaceuticals and Valneva SE

DUBLIN, Oct. 9, 2019 /PRNewswire/ -- The "Lyme Disease - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The Lyme Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lyme Disease...

Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15

Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15
Show more

Valneva Blogs

Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate

Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate Phase 1 unblinded results up to month 7 showed an excellent immunogenicity and safety profile confirming Valneva´s unique, single-shot vaccine candidate These results stro

Valneva Announces Termination of 2013 Shareholder Agreement

Valneva Announces Termination of 2013 Shareholder Agreement Saint Herblain (France), April 3, 2019 Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, an

Valneva Announces the Availability of its FY 2018 Audited Consolidated and Statutory Financial Statements

Valneva Announces the Availability of its FY 2018 Audited Consolidated and Statutory Financial Statements Saint Herblain (France), March 21, 2019 Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for

Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019

Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019 Major R+D milestones achieved in 2018, double-digit product sales revenue growth delivered; Lyme and chikungunya programs expected to advance further i

Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate Saint-Herblain (France), January 31, 2019 Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious d

Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019 Saint Herblain (France), January 16, 2019 Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectio
Show more

Valneva Frequently Asked Questions

  • Who are Valneva key executives?

    Valneva's key executives are Thomas Lingelbach.

  • How many employees does Valneva have?

    Valneva has 17,686 employees.

  • Who are Valneva competitors?

    Competitors of Valneva include Morphic Therapeutic, Zealand Pharma and Diffusion Pharmaceuticals.

  • Where is Valneva headquarters?

    Valneva headquarters is located at 70, rue Saint Jean de Dieu, Lyon.

  • Where are Valneva offices?

    Valneva has offices in Lyon, Saint-Herblain, Gaithersburg, Wien and in 4 other locations.

  • How many offices does Valneva have?

    Valneva has 8 offices.